Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Organon & Co. (OGN)

NYSE Health Care Pharmaceuticals S&P SmallCap 600
$13.87
+0.08 (+0.58%)
Close of Nov 06, 2026 · end-of-day data
Source: Organon & Co.'s 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 02, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$7.78B$6.53B$6.30B$6.17B$6.26B$6.40B$6.22B
Cost of revenue$2.27B$2.12B$2.38B$2.29B$2.52B$2.69B$2.90B
Gross profit$5.50B$4.41B$3.92B$3.88B$3.75B$3.71B$3.31B
Research & development$220.00M$210.00M$443.00M$471.00M$528.00M$469.00M$366.00M
Selling, general & admin$1.44B$1.36B$1.67B$1.70B$1.89B$1.76B$1.72B
Interest expense$0$0$258.00M$422.00M$527.00M$520.00M$504.00M
Pre-tax income$3.70B$2.75B$1.53B$1.12B$673.00M$807.00M$425.00M
Income tax$390.00M$496.00M$178.00M$205.00M-$350.00M-$57.00M$238.00M
Net income$3.22B$2.16B$1.35B$917.00M$1.02B$864.00M$187.00M
EPS (basic)$12.69$8.52$5.33$3.61$4.01$3.36$0.72
EPS (diluted)$12.69$8.52$5.31$3.59$3.99$3.33$0.72
Diluted shares253.52M253.52M254.19M255.17M256.27M259.15M260.76M
Gross margin70.8%67.6%62.2%62.8%59.8%58.0%53.3%
Net margin41.4%33.1%21.4%14.9%16.3%13.5%3.0%

Balance sheet

fiscal years · USD
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$0$12.00M$737.00M$706.00M$693.00M$675.00M$574.00M
Receivables—$1.04B$1.38B$1.48B$1.74B$1.36B$1.33B
Inventory—$913.00M$915.00M$1.00B$1.31B$1.32B$1.41B
Total current assets—$3.57B$3.76B$3.93B$4.51B$4.35B$4.35B
Goodwill—$4.60B$4.60B$4.60B$4.60B$4.68B$4.15B
Total assets—$10.11B$10.68B$10.96B$12.06B$13.10B$12.87B
Total current liabilities—$2.67B$2.60B$2.51B$2.92B$2.72B$2.39B
Short-term debt—$0$9.00M$8.00M$9.00M$20.00M$16.00M
Long-term debt—$0$9.12B$8.90B$8.75B$8.86B$8.63B
Total debt—$0$9.13B$8.91B$8.76B$8.88B$8.64B
Total liabilities—$4.62B$12.19B$11.85B$12.13B$12.63B$12.12B
Shareholders' equity$7.04B$5.49B-$1.51B-$892.00M-$70.00M$472.00M$752.00M

Cash flow

fiscal years · USD
Fiscal yearFY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$3.02B$2.28B$2.16B$858.00M$799.00M$939.00M$700.00M
Capital expenditures$92.00M$255.00M$192.00M$196.00M$251.00M$175.00M$162.00M
Free cash flow$2.93B$2.03B$1.97B$662.00M$548.00M$764.00M$538.00M
Investing cash flow-$88.00M-$250.00M-$481.00M-$420.00M-$260.00M-$513.00M-$390.00M
Financing cash flow-$2.93B-$2.02B-$977.00M-$433.00M-$569.00M-$368.00M-$561.00M
Dividends paid$0$0$145.00M$290.00M$294.00M$297.00M$88.00M
Stock-based compensation$41.00M$40.00M$59.00M$75.00M$101.00M$105.00M$77.00M
Depreciation & amortization$49.00M$56.00M$92.00M$96.00M$120.00M$132.00M$156.00M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.